Loading...
Consensus recommendations from cardiology and gastroenterology societies endorse the use of proton-pump inhibitors (PPIs) in patients who receive antiplatelet therapy and are at high risk for gastrointestinal bleeding (Am J Gastroenterol 2008; 103:2890). However, data from recent observational studies have suggested that PPI use might attenuate the antiplatelet effect of the thienopyridine clopidogrel in patients who receive it after an acute coronary syndrome (ACS) event. Moreover, one study identified a significantly higher composite rate of all-cause mortality and rehospitalization for ACS in patients who took both a PPI and clopidogrel than in those who took clopidogrel alone (JW Gastroenterol Mar 6 2009). To assess the effects of PPI u…